(Q48022229)

English

Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study

scientific article published on 10 April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

1 reference

based on heuristic

acute myeloid leukemia

1 reference

based on heuristic

Yukio Kobayashi

1

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

2

object named as

Kensei Tobinai

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

19

object named as

Noriko Usui

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

author name string

Akihiro Takeshita

3

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Kensuke Naito

4

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Osamu Asai

5

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Nobuaki Dobashi

6

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Shinpei Furusawa

7

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Kenji Saito

8

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Kinuko Mitani

9

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Yasuo Morishima

10

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Michinori Ogura

11

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Fumiaki Yoshiba

12

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Tomomitsu Hotta

13

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Masami Bessho

14

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Shin Matsuda

15

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Jin Takeuchi

16

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Shuichi Miyawaki

17

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Tomoki Naoe

18

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Ryuzo Ohno

20

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

publication date

10 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

89

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

4

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

460-469

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

https://scigraph.springernature.com/pub.10.1007/s12185-009-0298-1

0 references

Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/19360457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/19360457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19360457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate

1 reference

https://pubmed.ncbi.nlm.nih.gov/19360457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19360457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/19360457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19360457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19360457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19360457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19360457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model

1 reference

https://pubmed.ncbi.nlm.nih.gov/19360457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19360457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-009-0298-1

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/19360457

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48022229&oldid=2181868193"